1. Home
  2. HTCR vs OGEN Comparison

HTCR vs OGEN Comparison

Compare HTCR & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

N/A

Current Price

$2.06

Market Cap

3.5M

Sector

Technology

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.48

Market Cap

2.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HTCR
OGEN
Founded
2009
1996
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
2.8M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
HTCR
OGEN
Price
$2.06
$0.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.9K
29.1K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
87.84%
N/A
EPS Growth
414.29
N/A
EPS
N/A
N/A
Revenue
$30,407,229.00
N/A
Revenue This Year
$123.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.48
52 Week High
$3.97
$1.45

Technical Indicators

Market Signals
Indicator
HTCR
OGEN
Relative Strength Index (RSI) 37.31 40.59
Support Level $2.01 $0.49
Resistance Level $3.82 $0.59
Average True Range (ATR) 0.20 0.02
MACD -0.06 -0.00
Stochastic Oscillator 32.11 24.09

Price Performance

Historical Comparison
HTCR
OGEN

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: